The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
Status:
Completed
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
A phase 1, randomized, double-blind, parallel group, single-dose study to compare the
pharmacokinetics, pharmacodynamics and safety of two formulations of Omalizumab (CMAB007 and
Xolair) in healthy subjects.